Activins in reproductive biology and beyond

Human Reproduction Update

Volumn 22, Issue 3, 2016, Pages 342-357

  Wijayarathna, R ^a,b   de Kretser, D M ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Activin; Cancer; Follistatin; Inflammation; Inhibin; Ovary; Placenta; Pre eclampsia; Pregnancy; Testis

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ACTIVIN; ACTIVIN A; ACTIVIN C; ACTIVIN RECEPTOR; FOLLISTATIN; FOLLITROPIN; INHIBIN; MYELOPID; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; GLYCOPROTEIN; INHIBIN BETA A SUBUNIT;

AGING; ARTICLE; BIOLOGICAL ACTIVITY; CELL MATURATION; CELL PROLIFERATION; DECIDUALIZATION; DEVELOPMENTAL BIOLOGY; ECTOPIC PREGNANCY; EMBRYO INDUCTION; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FOLLITROPIN BLOOD LEVEL; GERM CELL; GESTATION PERIOD; GRANULOSA CELL; HUMAN; INTRAUTERINE GROWTH RETARDATION; MALE GENITAL SYSTEM; MENSTRUATION; MORPHOGENESIS; NONHUMAN; OOCYTE MATURATION; OVARY DEVELOPMENT; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; REPRODUCTION; SERTOLI CELL; SIGNAL TRANSDUCTION; SPONTANEOUS ABORTION; STEROIDOGENESIS; TESTIS DEVELOPMENT; UTERINE CERVIX CANCER; ANIMAL; CHEMISTRY; FEMALE; MALE; OVARY; OVARY TUMOR; PHYSIOLOGY; PREGNANCY; TESTIS;

ACTIVINS; ANIMALS; FEMALE; FOLLISTATIN; GLYCOPROTEINS; HUMANS; INHIBIN-BETA SUBUNITS; INHIBINS; MALE; OVARIAN NEOPLASMS; OVARY; PRE-ECLAMPSIA; PREGNANCY; REPRODUCTION; TESTIS;

EID: 84965057983     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmv058     Document Type: Article

References (194)

1. Al-Edani T, Assou S, Ferrieres A, Bringer Deutsch S, Gala A, Lecellier CH, Ait-Ahmed O, Hamamah S. Female aging alters expression of human cumulus cells genes that are essential for oocyte quality. Biomed Res Int 2014;2014:10 pages.
2. Alak BM, Coskun S, Friedman CI, Kennard EA, Kim MH, Seifer DB. ActivinAstimulates meiotic maturation of human oocytes and modulates granulosa cell steroidogenesis in vitro. Fertil Steril 1998;70:1126-1130.
3. Anderson RA, Evans LW, Irvine DS, McIntyreMA, GroomeNP, Riley SC. Follistatin and activin A production by the male reproductive tract. Hum Reprod 1998; 13:3319-3325.
4. Archambeault DR, Yao HH. Activin A, a product of fetal Leydig cells, is a unique paracrine regulator of Sertoli cell proliferation and fetal testis cord expansion. Proc Natl Acad Sci USA 2010;107:10526-10531.
5. Ball EMA, Risbridger GP. Activins as regulators of branching morphogenesis. Dev Biol 2001;238:1-12.
6. Barakat B, O'Connor AE, Gold E, de Kretser DM, Loveland KL. Inhibin, activin, follistatin and FSH serum levels and testicular production are highly modulated during the first spermatogenic wave in mice. Reproduction 2008;136:345-359.
7. Boitani C, Stefanini M, Fragale A, Morena AR. Activin stimulates Sertoli cell proliferation in a defined period of rat testis development. Endocrinology 1995;136:5438-5444.
8. Bouras M, Tabone E, Bertholon J,Sommer P, Bouvier R, Droz J-P, Benahmed M.Anovel SMAD4 gene mutation in seminoma germ cell tumors. Cancer Res 2000; 60:922-928.
9. Brown CW, Houston-Hawkins DE,Woodruff TK, Matzuk MM. Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat Genet 2000;25:453-457.
10. Bush KT, Sakurai H, Steer DL, Leonard MO, Sampogna RV, Meyer TN, Schwesinger C, Qiao J, Nigam SK. TGF-b superfamily members modulate growth, branching, shaping, and patterning of the ureteric bud. Dev Biol 2004;266:285-298.
11. Buzzard JJ, Farnworth PG, de Kretser DM, O'Connor AE, Wreford NG, Morrison JR. Proliferative phase Sertoli cells display a developmentally regulated response to activin in vitro. Endocrinology 2003;144:474-483.
12. Buzzard JJ, Loveland KL, O'Bryan MK, O'Connor AE, Bakker M, Hayashi T, Wreford NG, Morrison JR, de Kretser DM. Changes in circulating and testicular levels of inhibin A and B and activin A during postnatal development in the rat. Endocrinology 2004;145:3532-3541.
13. Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar R, Underwood KW, Pearsall RS, Lachey JL. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol 2010; 109:635-642.
14. Cancilla B, JarredRA,Wang H, Mellor SL,CunhaGR,RisbridgerGP.Regulation of prostate branching morphogenesis by activin A and follistatin. Dev Biol 2001;237:145-158.
15. Chantry AD, Heath D, Mulivor AW, Pearsall S, Baud'huin M, Coulton L, Evans H, Abdul N, Werner ED, Bouxsein ML et al. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 2010;25:2633-2646.
16. Chen JL, Walton KL, Winbanks CE, Murphy KT, Thomson RE, Makanji Y, Qian H, Lynch GS, Harrison CA, Gregorevic P. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J 2014;28:1711-1723.
17. Chen JL, Walton KL, Al-Musawi SL, Kelly EK, Qian H, La M, Lu L, Lovrecz G, Ziemann M, Lazarus R et al. Development of novel activin-targeted therapeutics. Mol Ther 2015;23:434-444.
18. Cheng J-C, Chang H-M, Qiu X, Fang L, Leung PCK. FOXL2-induced follistatin attenuates activin A-stimulated cell proliferation in human granulosa cell tumors. Biochem Biophys Res Commun 2014;443:537-542.
19. Chiu CS, Peekhaus N,Weber H, Adamski S, Murray EM, Zhang HZ, Zhao JZ, Ernst R, Lineberger J, Huang L et al. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents. J Gerontol A Biol Sci Med Sci 2013; 68:1181-1192.
20. Cipriano SC, Chen L, Kumar TR, Matzuk MM. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 2000;141:2319-2327.
21. Cobellis L, Cataldi P, Reis F, De Palo G, Raspagliesi F, Pilotti S, Arcuri F, Petraglia F. Gonadal malignant germ cell tumors express immunoreactive inhibin/activin subunits. Eur J Endocrinol 2001;145:779-784.
22. Daponte A, Deligeoroglou E, Garas A, Pournaras S, Hadjichristodoulou C, Messinis IE. ActivinAand follistatin as biomarkers for ectopic pregnancy and missed abortion. Dis Markers 2013;35:497-503.
23. de Kretser DM, Robertson DM. The isolation and physiology of inhibin and related proteins. Biol Reprod 1989;40:33-47.
24. de Kretser DM, Hedger MP, Loveland KL, Phillips DJ. Inhibins, activins and follistatin in reproduction. Hum Reprod Update 2002;8:529.
25. de Kretser DM, Bensley JG, Pettilä V, Linko R, Hedger MP, Hayward S, Allan CA, McLachlan RI, Ludlow H, Phillips DJ. Serum activin A and B levels predict outcome in patients with acute respiratory failure: a prospective cohort study. Crit Care 2013;17:R263.
26. de Winter J, Vanderstichele H, Timmerman M, Blok L, Themmen A, de Jong F. Activin is produced by rat Sertoli cells in vitro and can act as an autocrine regulator of Sertoli cell function. Endocrinology 1993;132:975-982.
27. de Winter JP, Vanderstichele HM, Verhoeven G, Timmerman MA, Wesseling JG, de Jong FH. Peritubular myoid cells from immature rat testes secrete activin-A and express activin receptor type II in vitro. Endocrinology 1994;135:759-767.
28. Dias VL, Rajpert-De Meyts E, McLachlan R, Loveland KL. Analysis of activin/ TGFB-signaling modulators within the normal and dysfunctional adult human testis reveals evidence of altered signaling capacity in a subset of seminomas. Reproduction 2009;138:801-811.
29. Diesch CH, HolzgreveW, Hahn S, Zhong XY. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn 2006;26:1267-1270.
30. Drummond AE, Le MT, Ethier J-F, Dyson M, Findlay JK. Expression and localization of activin receptors, Smads, and betaglycan to the postnatal rat ovary. Endocrinology 2002;143:1423-1433.
31. Dutta DJ, Zameer A, Mariani JN, Zhang J, Asp L, Huynh J, Mahase S, Laitman BM, Argaw AT, Mitiku N et al. Combinatorial actions of TGF-b and activin ligands promote oligodendrocyte development and CNS myelination. Development 2014; 141:2414-2428.
32. Eldar-Geva T, Spitz IM, GroomeNP, Margalioth EJ, Homburg R. Follistatin and activinA serum concentrations in obese and non-obese patients with polycystic ovary syndrome. Hum Reprod 2001;16:2552-2556.
33. Elito JJP, OliveiraLGP, SilvaMOFMD,Araujo EJP,CamanoLP. Serum activinAlevels and tubal ectopic pregnancy. Iran J Reprod Med 2014;12:227-228.
34. Erickson GF, Kokka S, Rivier C. Activin causes premature superovulation. Endocrinology 1995;136:4804-4813.
35. Esch FS, Shimasaki S, Mercado M, Cooksey K, Ling N, Ying S, Ueno N, Guillemin R. Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol 1987;1:849-855.
36. Fang J, YinW, Smiley E,Wang SQ, Bonadio J. Molecular cloning of the mouse activin bE subunit gene. Biochem Biophys Res Commun 1996;228:669-674.
37. Feijen A, Goumans MJ, van den AJ, Raaij E-V. Expression of activin subunits, activin receptors and follistatin in postimplantation mouse embryos suggests specific developmental functions for different activins. Development 1994;120:3621-3637.
38. FengZM, Madigan MB, Chen CL. Expression of type II activin receptor genes in the male and female reproductive tissues of the rat. Endocrinology 1993;132:2593-2600.
39. Ferguson CA, Tucker AS, Christensen L, Lau AL, Matzuk MM, Sharpe PT. Activin is an essential early mesenchymal signal in tooth development that is required for patterning of the murine dentition. Genes Dev 1998;12:2636-2649.
40. Fitzpatrick E, Johnson MP, Dyer TD, Forrest S, Elliott K, Blangero J, Brennecke SP, Moses EK. Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Mol Hum Reprod 2009;15:195-204.
41. Florio P, Severi FM, Bocchi C, Luisi S, Mazzini M, Danero S, Torricelli M, Petraglia F. Single serum activin a testing to predict ectopic pregnancy. J Clin Endocrinol Metab 2007;92:1748-1753.
42. Gallinelli A, Gallo R, Genazzani A, Matteo M, Caruso A, Woodruff T, Petraglia F. Episodic secretion of activin A in pregnant women. Eur J Endocrinol 1996; 135:340-344.
43. Gold E, Risbridger G. Activins and activin antagonists in the prostate and prostate cancer. Mol Cell Endocrinol 2012;359:107-112.
44. Gold EJ, O'Bryan MK, Mellor SL, Cranfield M, Risbridger GP, Groome NP, Fleming JS. Cell-specific expression of bC-activin in the rat reproductive tract, adrenal and liver. Mol Cell Endocrinol 2004;222:61-69.
45. Gold E, Marino FE, Harrison C, Makanji Y, Risbridger G. Activin-bc reduces reproductive tumour progression and abolishes cancer-associated cachexia in inhibin-deficient mice. J Pathol 2013;229:599-607.
46. Gonzalez CR, Matzkin ME, Frungieri MB, Terradas C, Ponzio R, Puigdomenech E, Levalle O, Calandra RS, Gonzalez-Calvar SI. Expression of the TGF-b1 system in human testicular pathologies. Reprod Biol Endocrinol 2010;8:148.
47. Guo Q, Kumar TR,Woodruff T, Hadsell LA, Demayo FJ, Matzuk MM. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol 1998;12:96-106.
48. Guo S, Mao X, He F, Liu H, Ming L. Activin Asupplement in the hESCs culture enhances the endoderm differentiation efficiency. Cell Biol Int 2014;38:849-856.
49. Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Saito S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab 1996;81:2125-2130.
50. Hardy CL, King SJ, Mifsud NA, Hedger MP, Phillips DJ, Mackay F, de Kretser DM, Wilson JW, Rolland JM, O'Hehir RE. The activin A antagonist follistatin inhibits cystic fibrosis-like lung inflammation and pathology. Immunol Cell Biol 2015; 93:567-574.
51. Harrison CA, Gray PC, Vale WW, Robertson DM. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005; 16:73-78.
52. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells: endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 1997;272:13835-13842.
53. Hedger MP, de Kretser DM. The activins and their binding protein, follistatin-diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev 2013;24:285-295.
54. Hedger MP, Winnall WR, Phillips DJ, de Kretser DM. Chapter Thirteen-The regulation and functions of activin and follistatin in inflammation and immunity. In: Gerald L (ed). Vitam Horm. Academic Press, 2011, 255-297.
55. Heldin C-H, Miyazono K, ten Dijke P. TGF-b signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.
56. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang X-F, Rich JN. SB-431542, a small molecule transforming growth factor-b-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004;3:737-745.
57. Hofland J, van Weerden WM,Steenbergen J, Dits NFJ, Jenster G, de Jong FH. Activin A stimulates AKR1C3 expression and growth in human prostate cancer. Endocrinology 2012;153:5726-5734.
58. Hogan BL, Blessing M, Winnier GE, Suzuki N, Jones CM. Growth factors in development: the role of TGF-b related polypeptide signalling molecules in embryogenesis. Dev Suppl 1994;53-60.
59. Holdsworth-Carson SJ, Craythorn RG, Winnall WR, Dhaliwal K, Genovese R, Nowell CJ, Rogers PAW, de Kretser DM, Hedger MP, Girling JE. Follistatin is essential for normal postnatal development and function of mouse oviduct and uterus. Reprod Fertil Dev 2014;27:985-999.
60. Horne AW, van den Driesche S, King AE, Burgess S, Myers M, Ludlow H, Lourenco P, Ghazal P, Williams AR, Critchley HO et al. Endometrial inhibin/activin beta-B subunit expression is related to decidualization and is reduced in tubal ectopic pregnancy. J Clin Endocrinol Metab 2008;93:2375-2382.
61. Hotten G, Neidhardt H, Schneider C, Pohl J. Cloning of a new member of the TGF-b family: a putative new activin bC chain. Biochem Biophys Res Commun 1995; 206:608-613.
62. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-b superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74.
63. Inouye S, Guo Y, Depaolo L, Shimonaka M, Ling N, Shimasaki S. Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin. Endocrinology 1991; 129:815-822.
64. Jones KL, Brauman JN, Groome NP, de Kretser DM, Phillips DJ. Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 2000a;141:1905-1908.
65. Jones RL, Salamonsen LA, Critchley HOD, Rogers PAW, Affandi B, Findlay JK. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. Mol Hum Reprod 2000b;6:1107-1117.
66. Jones RL, Salamonsen LA, Findlay JK. Activin A promotes human endometrial stromal cell decidualization in vitro. J Clin Endocrinol Metab 2002a;87:4001-4004.
67. Jones RL, Salamonsen LA, Zhao YC, Ethier J-F,Drummond AE, Findlay JK. Expression of activin receptors, follistatin and betaglycan by human endometrial stromal cells; consistent with a role for activins during decidualization. Mol Hum Reprod 2002b; 8:363-374.
68. Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM,Phillips DJ. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci USA 2007; 104:16239-16244.
69. Kaitu'u-Lino TUJ, Phillips DJ, Morison NB, Salamonsen LA. A new role for activin in endometrial repair after menses. Endocrinology 2009;150:1904-1911.
70. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochin Biophys Acta 2005;1754:253-262.
71. Keogh EJ, Lee VWK, Rennie GC, Burger HG, Hudson B, de Kretser DM. Selective suppression of FSH by testicular extracts. Endocrinology 1976;98:997-1004.
72. Kim SK, Hebrok M, Li E, Oh SP, Schrewe H, Harmon EB, Lee JS, Melton DA. Activin receptor patterning of foregut organogenesis. Genes Dev 2000;14:1866-1871.
73. Klein NA, Battaglia DE, Woodruff TK, Padmanabhan V, Giudice LC, Bremner WJ, Soules MR. Ovarian follicular concentrations of activin, follistatin, inhibin, insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-2 (IGFBP-2), IGFBP-3, and vascular endothelial growth factor in spontaneous menstrual cycles of normal women of advanced reproductive age. J Clin Endocrinol Metab 2000; 85:4520-4525.
74. Lee W, Mason AJ, Schwall R, Szonyi E, Mather JP. Secretion of activin by interstitial cells in the testis. Science 1989;243:396-398.
75. Lerch TF, Shimasaki S,Woodruff TK, Jardetzky TS. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. J Biol Chem 2007; 282:15930-15939.
76. Leto G, Incorvaia L, Badalamenti G, Tumminello F, Gebbia N, Flandina C, Crescimanno M, Rini G. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006;23:117-122.
77. Leung PH, Salamonsen LA, Findlay JK. Immunolocalization of inhibin and activin subunits in human endometrium across the menstrual cycle. Hum Reprod 1998; 13:3469-3477.
78. Li R, Phillips DM, Mather JP. Activin promotes ovarian follicle development in vitro. Endocrinology 1995;136:849-856.
79. Lim R, Acharya R, Delpachitra P, Hobson S, Sobey CG, Drummond GR,Wallace EM. Activin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studies. Am J Obstet Gynecol 2015;212:86e1-8612.
80. Lin SJ, Lerch TF, Cook RW, Jardetzky TS,Woodruff TK. The structural basis of TGF-b, bone morphogenetic protein, and activin ligand binding. Reproduction 2006; 132:179-190.
81. Lin S-Y, Craythorn RG, O'Connor AE, Matzuk MM, Girling JE, Morrison JR, de Kretser DM. Female infertility and disrupted angiogenesis are actions of specific follistatin isoforms. Mol Endocrinol 2008;22:415-429.
82. Ling N, Ying SY, Ueno N, Esch F, Denoroy L, Guillemin R. Isolation and partial characterization of a Mr 32,000 protein with inhibin activity from porcine follicular fluid. Proc Natl Acad Sci USA 1985;82:7217-7221.
83. Ling N, Ying S-Y, Ueno N, Shimasaki S, Esch F, Hotta M, Guillemin R. Pituitary FSH is released by a heterodimer of the b subunits from the two forms of inhibin. Obstet Gynecol Surv 1987;42:109-111.
84. Link BA, Nishi R. Opposing effects of activin A and follistatin on developing skeletal muscle cells. Exp Cell Res 1997;233:350-362.
85. Loomans H, Andl C. Intertwining of activin A and TGF-b signaling: dual roles in cancer progression and cancer cell invasion. Cancers 2014;7:70-91.
86. Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J, Fajardo RJ, Kumar R, Underwood KW, Seehra J et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46:1082-1088.
87. Loumaye A, de Barsy M, Nachit M, Lause P, Frateur L, van Maanen A, Trefois P, Gruson D, Thissen JP. Role of activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab 2015;100:2030-2038.
88. Loveland KL, McFarlane JR, de Kretser DM. Expression of activin bC subunit mRNA in reproductive tissues. J Mol Endocrinol 1996;17:61-65.
89. Luisi S, Florio P, D'Antona D, Severi FM, Sanseverino F, Danero S, Petraglia F. Maternal serum inhibin A levels are a marker of a viable trophoblast in incomplete and complete miscarriage. Eur J Endocrinol 2003;148:233-236.
90. Maeshima A, Yamashita S, Maeshima K, Kojima I, Nojima Y. Activin a produced by ureteric bud is a differentiation factor for metanephric mesenchyme. J Am Soc Nephrol 2003;14:1523-1534.
91. Maeshima A, Mishima K, Yamashita S, Nakasatomi M, Miya M, Sakurai N, Sakairi T, Ikeuchi H, Hiromura K, Hasegawa Y et al. Follistatin, an activin antagonist, ameliorates renal interstitial fibrosis in a rat model of unilateral ureteral obstruction. Biomed Res Int 2014;2014:10.
92. Marchetti C, Hamdane M, Mitchell V, Mayo K, Devisme L, Rigot JM, Beauvillain JC, Hermand E, Defossez A. Immunolocalization of inhibin and activin a and bB subunits and expression of corresponding messenger RNAs in the human adult testis. Biol Reprod 2003;68:230-235.
93. Marino FE, Risbridger G, Gold E. The inhibin/activin signalling pathway in human gonadal and adrenal cancers. Mol Hum Reprod 2014;20:1223-1237.
94. Marino FE, Risbridger G, Gold E. Activin bC modulates gonadal, but not adrenal tumorigenesis in the inhibin deficient mice. Mol Cell Endocrinol 2015;409:41-50.
95. Martins da Silva SJ, Bayne RAL, Cambray N, Hartley PS, McNeilly AS, Anderson RA. Expression of activin subunits and receptors in the developing human ovary: activin A promotes germ cell survival and proliferation before primordial follicle formation. Dev Biol 2004;266:334-345.
96. Mather JP, Attie KM, Woodruff TK, Rice GC, Philips DM. Activin stimulates spermatogonial proliferation in germ-Sertoli cell cocultures from immature rat testis. Endocrinology 1990;127:3206-3214.
97. Mathews LS, Vale WW. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 1991;65:973-982.
98. Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, Aburatani H, Mishima HK, Imamura T, Miyazono K et al. SB-431542 and Gleevec inhibit transforming growth factor-b induced proliferation of human osteosarcoma cells. Cancer Res 2003;63:7791-7798.
99. Matzuk MM,Finegold MJ, Su JG, Hsueh AJ, Bradley A.Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 1992;360:313-319.
100. Matzuk MM, Kumar TR, Bickenbach JR, Vassalli A, Roop DR, Jaenisch R, Bradley A. Functional analysis of activins during mammalian development. Nature 1995a; 374:354-356.
101. Matzuk MM, Kumar TR, Bradley A. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature 1995b;374:356-360.
102. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal death in mice deficient in follistatin. Nature 1995c;374:360-363.
103. Matzuk MM, Kumar TR, Shou W, Coerver KA, Lau AL, Behringer RR, Finegold MJ. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog Horm Res 1996;51:123-151.
104. McLachlan RI, Healy DL, Robertson DM, Burger HG, de Kretser DM. The human placenta: a novel source of inhibin. Biochem Biophys Res Commun 1986; 140:485-490.
105. McLean AB, D'Amour KA, Jones KL, Krishnamoorthy M, Kulik MJ, Reynolds DM, Sheppard AM, Liu H, Xu Y, Baetge EE et al. Activin A efficiently specifies definitive endoderm from human embryonic stem cells only when Phosphatidylinositol 3-Kinase signaling is suppressed. Stem Cells 2007;25:29-38.
106. McPherson S, Thomas T, Wang H, Gurusinghe C, Risbridger G. Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol 1997;154:535-545.
107. McPherson SJ, Mellor SL,Wang H, Evans LW, Groome NP, Risbridger GP. Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 1999;140:5303-5309.
108. Meehan T, Schlatt S, O'Bryan MK, de Kretser DM, Loveland KL. Regulation of germ cell and Sertoli cell development by activin, follistatin, and FSH. Dev Biol 2000; 220:225-237.
109. Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, Risbridger GP. Localization of activin bA ,bB, and bC subunits in human prostate and evidence for formation of new activin heterodimers of bC subunit. J Clin Endocrinol Metab 2000;85:4851-4858.
110. Mellor SL, Ball EMA, O'Connor AE, Ethier J-F, Cranfield M, Schmitt JF, Phillips DJ, Groome NP, Risbridger GP. Activin bC subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology 2003; 144:4410-4419.
111. Mendis SHS, Meachem SJ, Sarraj MA, Loveland KL. Activin A balances Sertoli and germ cell proliferation in the fetal mouse testis. Biol Reprod 2011;84:379-391.
112. Merino R, Macias D, Ganan Y, Rodriguez-Leon J, Economides AN, Rodriguez-Esteban C, Izpisua-Belmonte JC, Hurle JM. Control of digit formation by activin signalling. Development 1999;126:2161-2170.
113. Michel U, Gerber JE, O'Connor A, Bunkowski S, BrückW, Nau R, Phillips DJ. Increased activin levels in cerebrospinal fluid of rabbits with bacterial meningitis are associated with activation of microglia. J Neurochem 2003;86:238-245.
114. Mithraprabhu S, Mendis S, Meachem SJ, Tubino L, Matzuk MM, Brown CW, Loveland KL. Activin bioactivity affects germ cell differentiation in the postnatal mouse testis in vivo. Biol Reprod 2010;82:980-990.
115. Morpurgo PS, Cetin I, Borgato S, Cortelazzi D, Nobile-DeSantis MS, Vaghi I, Beck-Peccoz P. Circulating levels of inhibin A, inhibin B and activin A in normal and intrauterine growth restricted (IUGR) fetuses. Eur J Obstet Gynecol Reprod Biol 2004;117:38-44.
116. Moses EK, Fitzpatrick E, Freed KA, Dyer TD, Forrest S, Elliott K, Johnson MP, Blangero J, Brennecke SP. Objective prioritization of positional candidate genes at a quantitative trait locus for pre-eclampsia on 2q22. Mol Hum Reprod 2006;12:505-512.
117. Muttukrishna S, Knight PG, Groome NP, Redman CWG, Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997; 349:1285-1288.
118. Muttukrishna S, North RA, Morris J, Schellenberg J-C, Taylor RS, Asselin J, Ledger W, Groome N, Redman CWG. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 2000;15:1640-1645.
119. Muttukrishna S, Jauniaux E, Greenwold N, McGarrigle H, Jivraj S, Carter S, Elgaddal S, Groome N, Regan L. Circulating levels of inhibin A, activin A and follistatin in missed and recurrent miscarriages. Hum Reprod 2002;17:3072-3078.
120. Muttukrishna S, Tannetta D, Groome N, Sargent I. Activin and follistatin in female reproduction. Mol Cell Endocrinol 2004a;225:45-56.
121. Muttukrishna S, Bearfield C, Johns J, Jauniaux E. Inhibin, activin, follistatin, activin receptors and beta-glycan gene expression in the villous tissue of miscarriage patients. Mol Hum Reprod 2004b;10:793-798.
122. Muttukrishna S, Hyett J, Paine M, Moodley J, Groome N, Rodeck C. Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients. Clin Endocrinol 2006;64:469-473.
123. Mylonas I. Inhibin beta B: a useful tumor marker in uterine endometrioid adenocarcinomas? Histol Histopathol 2011;26:1415-1422.
124. Mylonas I, Schiessl B, Jeschke U, Vogl J, Makrigiannakis A, Kuhn C, Kunze S, Schulze S, Kainer F, Friese K. Expression of inhibin/activin subunits alpha (a), beta A (bA) and beta B bB) in placental tissue of normal and intrauterine growth restricted (IUGR) pregnancies. J Mol Histol 2006;37:43-52.
125. Mylonas I, Makovitzky J, Kunze S, Brüning A, Kainer F, Schiessl B. Inhibin-betaC subunit expression in normal and pathological human placental tissues. Syst Biol Reprod Med 2011;57:197-203.
126. Näf S, Escote X, Ballesteros M, Yañez RE, Simón-Muela I, Gil P, Albaiges G, Vendrell J, Megia A. Serum activin A and follistatin levels in gestational diabetes and the association of the activin A-follistatin system with anthropometric parameters in offspring. PLoS One 2014;9:e92175.
127. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. Activin-binding protein from rat ovary is follistatin. Science 1990;247:836-838.
128. Nakamura T, Sugino K, Titani K, Sugino H. Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells. J Biol Chem 1991;266:19432-19437.
129. Nakamura T, Asashima M, Eto Y, Takio K, Uchiyama H, Moriya N, Ariizumi T, Yashiro T, Sugino K, Titani K et al. Isolation and characterization of native activin B. J Biol Chem 1992;267:16385-16389.
130. Narula A, Kilen S, Ma E, Kroeger J, Goldberg E,Woodruff TK. Smad4 overexpression causes germ cell ablation and leydig cell hyperplasia in transgenic mice. Am J Pathol 2002;161:1723-1734.
131. Naujok O, Diekmann U, Lenzen S. The generation of definitive endoderm from human embryonic stem cells is initially independent from activin A but requires canonical Wnt-signaling. Stem Cell Rev 2014;10:480-493.
132. Nicholls PK, Stanton PG, Chen JL, Olcorn JS, Haverfield JT, Qian H, Walton KL, Gregorevic P, Harrison CA. Activin signaling regulates Sertoli cell differentiation and function. Endocrinology 2012;153:6065-6077.
133. Norman RJ, Milner CR, Groome NP, Robertson DM. Circulating follistatin concentrations are higher and activin concentrations are lower in polycystic ovarian syndrome. Hum Reprod 2001;16:668-672.
134. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum Reprod 1999;14:827-832.
135. Oda S, Nishimatsu S, Murakami K, Ueno N. Molecular cloning and functional analysis of a new activin b subunit: a dorsal mesoderm-inducing activity in Xenopus. Biochem Biophys Res Commun 1995;210:581-588.
136. Okuma Y, O'Connor AE, Hayashi T, Loveland KL, de Kretser DM, Hedger MP. Regulated production of activin A and inhibin B throughout the cycle of the seminiferous epithelium in the rat. J Endocrinol 2006;190:331-340.
137. Ong CYT, Lioo AW, Munim S, Spencer K, Nicolaides KH. First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction. J Matern Fetal Neonatal Med 2004;15:176-180.
138. Otani T, Minami S, Kokawa K, Shikone T, Yamoto M, Nakano R. Immunohistochemical localization of activin A in human endometrial tissues during the menstrual cycle and in early pregnancy. Obstet Gynecol 1998;91:685-692.
139. Petraglia F, Vaughan J, Vale W. Inhibin and activin modulate the release of gonadotropin-releasing hormone, human chorionic gonadotropin, and progesterone from cultured human placental cells. Proc Natl Acad Sci USA 1989; 86:5114-5117.
140. Petraglia F, Calza L, Garuti GC, Abrate M, Giardino L, Genazzani AR, Vale W, Meunier H. Presence and synthesis of inhibin subunits in human decidua. J Clin Endocrinol Metab 1990;71:487-492.
141. Petraglia F, De Vita D, Gallinelli A, Aguzzoli L, Genazzani AR, Romero R,Woodruff TK. Abnormal concentration of maternal serum activin-A in gestational diseases. J Clin Endocrinol Metab 1995;80:558-561.
142. Petraglia F, Florio P, Luisi S, Gallo R, Gadducci A, Vigano` P, Blasio AMD, Genazzani AR, Vale W. Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. high levels of serum activin A in women with endometrial and cervical carcinoma. J Clin Endocrinol Metab 1998;83:1194-1200.
143. Phillips DJ, de Kretser DM. Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 1998;19:287-322.
144. Piestrzeniewicz-Ulanska D, Brys M, Semczuk A, Jakowicki JA, Krajewska WM. Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium. Cancer Lett 2002;186:231-239.
145. Prakash A, Li TC, Tuckerman E, Laird S,Wells M, Ledger WL. A study of luteal phase expression of inhibin, activin, and follistatin subunits in the endometrium of women with recurrent miscarriage. Fertil Steril 2006;86:1723-1730.
146. Reame NE, Lukacs JL, Olton P, Ansbacher R, Padmanabhan V. Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition. Fertil Steril 2007;88:1003-1005.
147. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One 2009;4:e4453.
148. Ritvos O, Tuuri T, Erämaa M, Sainio K, Hildén K, Saxén L, Gilbert SF. Activin disrupts epithelial branching morphogenesis in developing glandular organs of the mouse. Mech Dev 1995;50:229-245.
149. Roberts VJ, Barth S, el-Roeiy A, Yen SS. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle. J Clin Endocrinol Metab 1993; 77:1402-1410.
150. Robertson DM, Foulds LM, Leversha L, Morgan FJ, Hearn MTW, Burger HG, Wettenhall REH, de Kretser DM. Isolation of inhibin from bovine follicular fluid. Biochem Biophys Res Commun 1985;126:220-226.
151. Robertson DM, Klein R, de Vos FL, McLachlan RI, Wettenhall REH, Hearn MTW, Burger HG, de Kretser DM. The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 1987;149:744-749.
152. Roten LT, Johnson MP, Forsmo S, Fitzpatrick E, Dyer TD, Brennecke SP, Blangero J, Moses EK, Austgulen R. Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). Eur J Hum Genet 2008;17:250-257.
153. Santoro N, Adel T, Skurnick JH. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril 1999;71:658-662.
154. Schneider-Kolsky M, Manuelpillai U, Gargett C, Wallace EM. Activin bA-subunit and activin receptors in human myometrium at term and during labour. Br J Obstet Gynaecol 2001;108:869-874.
155. Schrewe H, Gendron-Maguire M, Harbison ML, Gridley T. Mice homozygous for a null mutation of activin beta B are viable and fertile. Mech Dev 1994;47:43-51.
156. Shen ZJ, Chen XP, Chen YG. Inhibin B, activin A, and follistatin and the pathogenesis of polycystic ovary syndrome. Int J Gynaecol Obstet 2005;88:336-337.
157. Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A, Ueno N, Ying SY, Ling N, Guillemin R. Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA 1988;85:4218-4222.
158. Silver HM, Lambert-Messerlian GM, Star JA,Hogan J,Canick JA. Comparison ofmaternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Am J Obstet Gynecol 1999;180:1131-1137.
159. Sokol S, Christian JL, Moon RT, Melton DA. Injected Wnt RNA induces a complete body axis in Xenopus embryos. Cell 1991;67:741-752.
160. Stern CD, Yu RT, Kakizuka A, Kintner CR, Mathews LS, Vale WW, Evans RM, Umesono K. Activin and its receptors during gastrulation and the later phases of mesoderm development in the chick embryo. Dev Biol 1995;172:192-205.
161. Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N, Titani K, Sugino H. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem 1993;268:15579-15587.
162. Sun T, Xin Z, Jin Z, Wu Y, Gong Y. Effect of TGF-b/Smad signaling on sertoli cell and possible mechanism related to complete sertoli cell-only syndrome. Mol Cell Biochem 2008;319:1-7.
163. Suragani RNVS, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS et al. Transforming growth factor-b superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 2014;20:408-414.
164. Tamminen JA, Yin M,Rönty M, Sutinen E, Pasternack A, Ritvos O, Myllärniemi M, Koli K. Overexpression of activin-A and -B in malignant mesothelioma-attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth. Exp Cell Res 2015;332:102-115.
165. Tanimoto Y, Tanimoto K, Sugiyama F, Horiguchi H, Murakami K, Yagami K-I, Fukamizu A. Male sterility in transgenic mice expressing activin bA subunit gene in testis. Biochem Biophys Res Commun 1999;259:699-705.
166. Teede H, Ng S, Hedger M, Moran L. Follistatin and activins in polycystic ovary syndrome: relationship to metabolic and hormonal markers. Metab Clin Exp 2013; 62:1394-1400.
167. Thompson TB, Lerch TF, Cook RW,Woodruff TK, Jardetzky TS. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 2005;9:535-543.
168. Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M et al. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett 2015;356:819-827.
169. Tomaszewski J, Joseph A, Archambeault D, Yao HHC. Essential roles of inhibin beta A in mouse epididymal coiling. Proc Natl Acad Sci USA 2007;104:11322-11327.
170. Tsuchida K, Nakatani M, Yamakawa N, Hashimoto O, Hasegawa Y, Sugino H. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol 2004;220:59-65.
171. Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA 1987; 84:8282-8286.
172. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spiess J. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986;321:776-779.
173. van Schaik RH, Wierikx CD, Looijenga LH, Oosterhuis JW, de Jong FH. Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs. Br J Cancer 1997;76:1191-1198.
174. Vassalli A, Matzuk MM, Gardner HA, Lee KF, Jaenisch R. Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. Genes Dev 1994;8:414-427.
175. Vihko KK, Blauer M, Puistola U, Tuohimaa P. Activin B in patients with granulosa cell tumors: serum levels in comparison to inhibin. Acta Obstet Gynecol Scand 2003; 82:570-574.
176. Wacker I, Sachs M, Knaup K, Wiesener M,Weiske J, Huber O, Akçetin Z, Behrens J. Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor. Mol Cell Biol 2009;29:1707-1718.
177. Wallace EM, Schneider-Kolsky ME, Edwards A, Baker L, Jenkin G. Maternal serum activin A levels in association with intrauterine fetal growth restriction. BJOG 2003; 110:306-310.
178. Wallace EM, Marjono B, Tyzack K, Tong S. First trimester levels of inhibins and activin A in normal and failing pregnancies. Clin Endocrinol 2004;60:484-490.
179. Walton KL, Makanji Y, Wilce MC, Chan KL, Robertson DM, Harrison CA. A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGF-b) ligands. J Biol Chem 2009;284:9311-9320.
180. Walton KL, Makanji Y, Chen J, Wilce MC, Chan KL, Robertson DM, Harrison CA. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem 2010;285:17029-17037.
181. Walton KL, Makanji Y, Harrison CA.Newinsights into themechanisms of activin action and inhibition. Mol Cell Endocrinol 2012;359:2-12.
182. Wang XP, Suomalainen M, Jorgez CJ, Matzuk MM, Wankell M, Werner S, Thesleff I. Modulation of activin/bone morphogenetic protein signaling by follistatin is required for the morphogenesis of mouse molar teeth. Dev Dyn 2004;231:98-108.
183. Warrick J, Gronowski A, Moffett C, Zhao Q, Bishop E,Woodworth A. Serum activinA does not predict ectopic pregnancy as a single measurement test, alone or as part of a multi-marker panel including progesterone and hCG. Clin Chim Acta 2012; 413:707-711.
184. Williamson RD, O'Keeffe GW, Kenny LC. Activin signalling and pre-eclampsia: from genetic risk to pre-symptomatic biomarker. Cytokine 2015;71:360-365.
185. Winnall WR, Wu H, Sarraj MA, Rogers PAW, de Kretser DM, Girling JE, Hedger MP. Expression patterns of activin, inhibin and follistatin variants in the adult male mouse reproductive tract suggest important roles in the epididymis and vas deferens. Reprod Fertil Dev 2013;25:570-580.
186. Woodruff TK, Lyon RJ, Hansen SE, Rice GC, Mather JP. Inhibin and activin locally regulate rat ovarian folliculogenesis. Endocrinology 1990;127:3196-3205.
187. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-b receptor. Nature 1994;370:341-347.
188. Wu H, Chen Y, Winnall WR, Phillips DJ, Hedger MP. Regulation of activin A release from murine bone marrow-derived neutrophil precursors by tumour necrosis factor-a and insulin. Cytokine 2013;61:199-204.
189. Xu X, Browning V, Odorico J. Activin, BMP and FGF pathways cooperate to promote endoderm and pancreatic lineage cell differentiation from human embryonic stem cells. Mech Dev 2011;128:412-427.
190. Ying S-Y, Zhang Z, Huang G. Expression and localization of inhibin/activin subunits and activin receptors in the normal rat prostate. Life Sci 1997;60:397-401.
191. Zarubin T, Han J. Activation and signaling of the p38MAPkinase pathway. Cell Res 2005; 15:11-18.
192. Zhang Z, Zhao Y, Batres Y, Lin M-F, Ying S-Y. Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun 1997;234:362-365.
193. Zhang Y-Q, Resta S, Jung B, Barrett KE, Sarvetnick N. Upregulation of activin signaling in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2009;297:G768-G780.
194. Zhao J, Lee M, Smith S, Warburton D. Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture. Dev Biol 1998;194:182-195.